Background: South Africa has the highest incidence of tuberculosis in the world, largely resulting from a high population prevalence of HIV infection. We investigated the incidence of microbiologically confi rmed pulmonary tuberculosis, and new cases of pulmonary tuberculosis registered for treatment, nationally and provincially in South Africa from 2004 to 2012, during which time there were changes in antiretroviral therapy (ART) coverage among individuals with HIV infection.
Introduction
South Africa has the highest annual incidence of tuberculosis per head, with WHO estimating 400 000 new cases in South Africa during 2012, the third highest absolute number of new cases worldwide. 1, 2 Robust tuberculosis surveillance data are needed to assess the eff ect of new or improved interventions such as diagnostic assays, enhanced case-detection programmes, isoniazid pre ventive therapy (IPT), and expansion of antiretroviral therapy (ART) to individuals with HIV infection. 3, 4 Despite the high incidence of tuberculosis in South Africa, uncertainties remain about the accuracy of these estimates. A national evaluation of microbiologically confi rmed pulmonary disease could be used to determine the veracity of incidence imputed from cases registered for tuberculosis treatment on the electronic TB databases (ETD) in South Africa. This analysis has not been previously undertaken, however, despite centralisation of tuberculosis microbiology testing in the public sector through the National Health Laboratory Service (NHLS). Longitudinal evaluation of the incidence of micro biologically confi rmed pulmonary tuberculosis in South Africa, where the population prevalence of HIV infection is 18% and 70% of people with tuberculosis are HIV-infected, can also inform whether a temporal association exists between trends in incidence of microbiologically confi rmed cases and increased access of HIV-infected individuals to ART. 3 We undertook a time series analysis of new cases of microbiologically confi rmed pulmonary tuberculosis and new cases of pulmonary tuberculosis registered for treatment in South Africa from 2004 to 2012, to identify trends in national and provincial incidence, in relation to the population prevalence of HIV and ART coverage in HIV-infected individuals.
Methods

Sources of data
In South Africa, there are three national sources of tuberculosis data: the NHLS Corporate Data Warehouse (CDW); and the National Department of Health's Electronic TB Register (ETR) and Electronic Drug Resistance Register (EDR), together forming what is referred to as the ETD. The usefulness of CDW as a source of data for tuberculosis surveillance has been recognised. 5 CDW is managed by the NHLS, the sole laboratory service provider for all public health facilities in South Africa (which serve 84% of the population) and also serves private-sector patients with tuberculosis that are routinely managed through state health services. 6 Data for all respiratory samples submitted to the NHLS for tuberculosis testing were identifi ed from CDW and unique, patient-level data generated. The Northern Cape absence of unique patient identifi ers required a series of record-linking processes to match multiple specimen records to individual patients as detailed in the appendix.
We defi ned a case of microbiologically confi rmed pulmonary tuberculosis as any case with at least one auramine smear-positive sample on microscopy, culture of Mycobacterium tuberculosis, or identifi cation of M tuberculosis by Xpert MTB/Rif (Cepheid, Sunnyvale, CA, USA), from respiratory secretion samples (all ages) or from gastric washings in children. Details of types of M tuberculosis diagnostic assays used at NHLS between 2004 and 2012 are provided in the appendix.
Because individuals could have been tested for tuberculosis several times for the same episode of illness, including multiple samples sent for tuberculosis pro gramme monitoring requirements, or visits to diff erent health facilities, a conservative 24-month interval was applied to distinguish new cases from preceding episodes or cases currently under treatment and follow-up.
The ETR and EDR are maintained by the national Department of Health to register and track the progress of individuals initiated on treatment for susceptible and drug-resistant tuberculosis, respectively. Data for new cases of pulmonary tuberculosis recorded in the EDR for the same period were extracted and combined with the ETR data to derive data for new cases of tuberculosis registered for treatment. The appendix includes a description of the data processing for this dataset.
We used annual mid-year population estimates to calculate incidence of pulmonary tuberculosis by province, age, and sex. 7 These estimates are based on government census data gathered every 5 years, with imputation of denominator data for the interim years. HIV prevalence and ART coverage over the relevant years are based on the Actuarial Sciences of South Africa AIDS and demographic model (detailed in the appendix), which is the only available source of ART data covering the total period of our study and is similar to other sources of data.
8,9
Statistical analysis
We investigated autoregressive and non-linear models to estimate trends in incidence of pulmonary tuberculosis, and selected the autoregressive models (up to 12th order) on the basis of fi t. Each model was fi tted to provincial and national data, excluding KwaZulu-Natal where data was only available for 2011 and 2012, because the laboratory system was largely paper-based in this province before 2011. We used data from the three provinces bordering KwaZulu-Natal, as well as available data for 2011 and 2012 for the province, to model incidence of microbiologically confi rmed tuberculosis for KwaZulu-Natal for 2004 to 2010. The fi nal models and details regarding model selection are provided in the appendix.
Annual incidence rates and the estimated structural portion of the model were plotted over time to assess the trends in tuberculosis at national, provincial, and age-group levels. To examine the association between ART and HIV infection with tuberculosis, model estimates for annual incidence of microbiologically confi rmed pulmonary tuberculosis and HIV/ART rates are plotted against time.
We used descriptive statistics to cross-tabulate, characterise, and compare groups. All data management and descriptive statistics were undertaken with Stata MP version 13.0. We used SAS/STAT software version 9.3 for all trend analyses.
Role of the funding source
Employees of the funder of the study were involved in study design, data collection, data analysis, data interpretation, and writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
We identifi ed 3 523 371 cases of microbiologically confi rmed pulmonary tuberculosis during the 9-year Incidence is reported per 100 000 population with corresponding 95% CIs shown in parentheses. * Table includes incidence estimates imputed for KwaZulu-Natal province from 2004 up to 2010 (because data for the province during this period were incomplete). (table 1) . Excluding KwaZulu-Natal province, for which only imputed incidence data were available from 2004 to 2010, more consistent decreases in national incidence were noted, from a peak of 802 per 100 000 population in 2008, falling to 674 per 100 000 population by 2012 (table 1) . During the period of this analysis, testing rates increased nationally and provincially in South Africa. Nationally (excluding KwaZulu-Natal province), the rate of testing for pulmonary tuberculosis (per 100 000 population) increased from 2926 in 2004, peaked at 6403 in 2011, and subsequently fell to 5616 by 2012 (appendix). Sensitivity analysis using a 12-month interval showed a less than 5% diff erence in incidence of microbiologically confi rmed pulmonary tuberculosis (appendix); therefore, all data reported uses the 24-month interval. The median age for cases of microbiologically confi rmed pulmonary tuberculosis was 35 years (IQR 28-45): 33 years (26-42) in females and 38 years (30-46) in males. Throughout the 9 years, the highest to lowest rank order of age groups for incidence of microbiologically confi rmed disease was 25-44 years, 45-64 years, 65 years or older, 15-24 years, and younger than 15 years in males, and 25-44 years, 15-24 years, 45-64 years, younger than 15 years, and 65 years or older in females (table 2). The age-group rank order of incidence of microbiologically confi rmed disease was similar to the age-group rank order of HIV prevalence, which was 19-21%, 12-13%, 1-2%, 2-4%, and 2-3% in the corresponding age-groups for males and 23-28%, 12-15%, 4-9%, 2-3%, and <1% for females, respectively (table 2). Trends in incidence of microbiologically confi rmed pulmonary tuberculosis were evident nationally and provincially and were similar across all age groups, increasing from 2004 to 2008, with declines seen until 2012 (fi gure 2). Overall, 54% of cases occurred in males. The incidence was greater among females than in males in the younger than 15 years and 15-24-year age groups, while being greater among males in older agegroups, especially in those aged 45-64 years (table 2) . This trend was mirrored by a higher population prevalence of HIV infection in women than men in the 15-24-year age group; and vice versa in those aged 45-64 years.
To explore a possible explanation for the reported trend in microbiologically confi rmed pulmonary tuberculosis, we examined the trend in HIV infection and ART coverage over the study period. Incidence of (table 1) , from a province constituting 20% of the South African population. 7 Western Cape was the fi rst province in which incidence of microbiologically confi rmed pulmonary tuberculosis started decreasing, with a 4-9% year-on-year decline from 2007 (1216 per 100 000 population) until 2012 (885 per 100 000 population; table 1, fi gure 2). Conversely, the incidence in the neighbouring Eastern Cape increased steadily by between 4% and 19% year-on-year from 2004 (719 per 100 000 population) until 2008 (1152 per 100 000 population), and remained relatively unchanged thereafter until 2012 (1095 per 100 000 population). In Gauteng, which constitutes 24% of the South African population, incidence of microbiologically confi rmed disease was stable from 2005 to 2008 (620-662 per 100 000 population), and decreased by 2-6% year-on-year from 2008 to 2011, and by 15% between 2011 (546 per 100 000 population) and 2012 (466 per 100 000 population). 7 Similar to the national trend, the decline in incidence of microbiologically confi rmed pulmonary tuberculosis in provinces such as Gauteng, North West, Northern Cape, and Western Cape occurred despite an increase in the rate of people tested for the disease (appendix), and an increase in the total number of tests undertaken (appendix). Provincial trends in incidence of microbiologically confi rmed disease coincided with ART programme expansion in the respective provinces, with earlier peaks Incidence of mPTB per 100 000 population with 95% CIs in parentheses. mPTB=microbiologically confi rmed pulmonary tuberculosis. in microbiologically confi rmed tuberculosis in provinces with earlier increases in ART coverage (fi gure 1). Analysis of the ETD showed that the trends in incidence of new cases of pulmonary tuberculosis registered for treatment were similar to those for microbiologically confi rmed disease, with both peaking in 2008-09, (appendix). Six of the nine provinces had peaks in incidence of registered cases between 2008 and 2009, whereas the incidence of registered cases peaked in the Western Cape in 2005 compared with 2006 for microbiologically confi rmed cases. For Gauteng and Northern Cape, cases registered for treatment could not be identifi ed because of missing or incomplete ETD data for several years in these provinces.
There were no statistically signifi cant diff erences in incidence between microbiologically confi rmed pulmonary tuberculosis and new cases registered for treatment in the North West and Free State provinces; however, the diff erences in incidence of microbiologically confi rmed pulmonary tuberculosis and cases registered for treatment were consistently higher nationally and in seven of the nine provinces (appendix). The percentage diff erence in national incidence rates for microbiologically confi rmed disease and cases registered for treatment ranged between 33% in 2006 and 11% in 2010, with a 16% diff erence seen in 2011-the only year with complete data from all provinces (appendix). The diff erence in incidence between microbiologically confi rmed cases and cases registered for treatment in the Western Cape decreased between 2004 (37%) and 2012 (20%). For KwaZulu-Natal and Gauteng, the gap was more than 50% in 2005 and 2006; although the gap declined over time, it remained above 25% from 2011.
Discussion
Our study identifi ed a 9% decline in incidence of microbiologically confi rmed pulmonary tuberculosis in South Africa in 2012 compared with its peak in 2008. This decrease in incidence occurred despite a continuing increase in HIV prevalence among South African adults, as well as the use of more sensitive diagnostic assays and higher testing rates for tuberculosis since 2008. We recorded an increase in incidence of microbiologically confi rmed pulmonary tuberculosis from 2004 to 2008, which coincided with an increase in prevalence of HIV/AIDS and limited use of ART; this was followed by a decrease in incidence from 2009 to 2012, which coincided with ART programme expansion in South Africa. The greatest decline in incidence of microbiologically confi rmed pulmonary tuberculosis (19% between 2008 and 2012) was in the 25-44-year age group, which also consistently had the highest prevalence of HIV infection; these results are similar to those reported in a previous study in Cape Town. 10 These fi ndings suggest that ART programme expansion is probably contributing to tuberculosis control in South Africa.
We noted that incidence rates of microbiologically confi rmed disease in Eastern Cape and KwaZulu-Natal peaked later and did not show similar declines to the other provinces and seem to be stabilising. This pattern could be caused by higher rates of HIV and tuberculosis co-infection in these provinces, coupled with slower expansion of ART programmes. These provinces might need continuing surveillance of and further studies on the eff ect of newer diagnostics and increased ART coverage on the burden of tuberculosis, and possibly targeted interventions. KwaZulu-Natal and Eastern Cape constitute 32% of the South African population but accounted for 48% of all cases of microbiologically confi rmed pulmonary tuberculosis in 2012.
To our knowledge, this study is the fi rst to provide a nationwide report from South Africa of subnational population-based rates of microbiologically confi rmed pulmonary tuberculosis (panel). Our incidence estimates, which excluded extrapulmonary cases (15-20% of immuno competent adult tuberculosis cases), 13 were higher than those reported by the yearly WHO Global tuberculosis Reports, which include all forms of tuberculosis notifi cations from the ETD. 1 WHO reports are based on data submitted shortly after the close of a year and these fi gures are often later revised upwards as outstanding data are received and entered onto the ETD. The laboratorybased surveillance system is passive and despite using the most recent ETD data for comparing incidence rates, underestimate, especially in areas where culture-based testing is not routine, and in the era before the introduction of Xpert MTB/Rif. 19 Furthermore, incidence of pulmonary tuberculosis in individuals younger than 15 years, which represented 3% of all microbiologically confi rmed cases in our study, is also likely to be an underestimate because of the low sensitivity of diagnostic assays in children, with cultures testing positive for M tuberculosis in only 10-40% of childhood tuberculosis cases. 20 The temporal link between the increase in microbiologically confi rmed pulmonary tuberculosis and increasing HIV prevalence seen here has been reported in other low-income countries with a high prevalence of HIV infection. 21 Similarly, temporal associations of declining tuberculosis rates after ART scale-up have been reported in a rural district of Malawi (33% reduction in 2 years) and in Cape Town (three-fold decline in tuberculosis incidence over 5 years). 22, 23 Important factors that aff ect laboratory-based tuberculosis surveillance data are diagnostic test availability and performance, as well as diff erential clinical application, both geographically and temporally. During the study period, there was a three-fold increase in testing rates since 2004, increased use of liquid-based culture from 2006 onwards, and the introduction of the Xpert MTB/Rif assay in 2011, which was expected to increase the number microbiologically confi rmed pulmonary tuberculosis was higher than new cases of pulmonary tuberculosis registered for treatment. Discordance between ETD and laboratory data has been previously described at a regional level, and has been attributed to incomplete electronic records, loss to follow-up of diagnosed cases, failure to initiate cases of microbiologically confi rmed disease on treatment, or death before accessing treatment. 14, 15 Although we were unable to integrate data for microbiologically confi rmed cases and new cases registered for treatment at a patient level, because of the absence of common unique identifi ers, overall trends in incidence of microbiologically confi rmed disease were similar to those for cases registered for treatment, with higher incidence of microbiologically confi rmed disease seen nationally and in seven of the nine provinces.
The overall percentage diff erence between microbiologically confi rmed pulmonary tuberculosis and new cases of the disease registered for treatment was lower nationally and in most provinces during the second half of the study period, coinciding with the decline in incidence of microbiologically confi rmed disease. This fi nding suggests that challenges in health systems capacity might have contributed to a larger gap in earlier years, which has since improved with successes in reducing the burden of disease. In a study undertaken in fi ve provinces in South Africa in 2009, the mean proportion of patients lost to follow-up was 25% and ranged between 21% and 34% for the sampled clinics in the respective provinces, which is similar to our fi ndings. 16 Temporal-spatial variations in the gap between incidence estimates for microbiologically confi rmed pulmonary tuberculosis and new cases registered for treatment were noted, which could be caused by both patient and provider factors. 17, 18 In 2012, this gap was more than 25% in fi ve of the nine provinces, which is concerning because patients not linked to care could be the major source of persisting M tuberculosis transmission in the community. Several limitations were also noted for data for new cases registered for treatment, including some provinces lacking or only having limited data for some years. Furthermore, apart from removal of obvious duplicates, no further deduplication was feasible with the available data.
The higher incidence of microbiologically confi rmed pulmonary tuberculosis cases compared with new cases of the disease registered for treatment is even more notable when considering that non-bacteriologically confi rmed cases are included in the data for cases registered for treatment. Also, most of the micro -biologically confi rmed cases we report were diagnosed by smear, which has only 25-30% sensitivity for diagnosing pulmonary tuberculosis in adults with HIV infection. Hence, although the laboratory-based surveillance provided a higher estimate of incidence of pulmonary tuberculosis in South Africa than did registries of patients on treatment, this itself is probably an
Panel: Research in context
Systematic review
We searched PubMed for original research that presented results for national and provincial incidence rates of tuberculosis in South Africa and its association with antiretroviral access published in English between Jan 1, 2003, and Dec 31, 2014. We combined search terms for tuberculosis/TB, incidence, and South Africa and looked for studies indicating temporal changes ("trends", "peak", "decline"), human immunodefi ciency virus ("HIV", "AIDS"), and antiretroviral access ("ARV", "ART", and "coverage"). Including systematic reviews, we identifi ed 135 studies with the terms "TB", "South Africa", and "incidence". Of these, 44 were in special populations, 31 were in limited geographical settings, 30 were on diagnostics and biomarkers, 17 were intervention studies, 11 were on extrapulmonary tuberculosis, eight were costing or modelling studies, three were immunological or vaccine research studies, and four were operations research studies. Only two studies were similar to our report, both of which were based on WHO and UNAIDS estimates but did not assess association with antiretroviral therapy (ART) coverage.
11,12
Interpretation To our knowledge, this is the fi rst comprehensive time series analysis of incidence rates for microbiologically confi rmed pulmonary tuberculosis in South Africa at a national and provincial level, with analysis of the association with HIV prevalence and ART coverage. We also highlight that current estimates of tuberculosis in South Africa, which are based on electronic TB registries, underestimate the incidence of tuberculosis, despite including non-microbiologically confi rmed cases of tuberculosis and extrapulmonary tuberculosis cases. Although the decline in tuberculosis incidence since 2008 in South Africa was temporally associated with an expansion of the ART programme among people with HIV infection, further modelling work is needed to determine the interaction of ART coverage and the incidence of tuberculosis in South Africa. of tuberculosis cases diagnosed by 30-37%. 24 This period also intensifi ed case fi nding as part of the HIVtuberculosis campaign during 2010. Despite these changes, which would have increased the sensitivity for diagnosing cases of microbiologically confi rmed pulmonary tuberculosis in South Africa, incidence declined from 2008. This focus on greater case detection and use of more sensitive diagnostic assays in the latter part of our analysis period might yet change the trend in tuberculosis incidence in the coming years despite the sustained ART coverage.
Although there was variability in provincial incidence of microbiologically confi rmed pulmonary tuberculosis, the overall trends over time were similar to those at the national level. These interprovincial diff erences, although likely to be multifactorial, could also be caused by diff erences in the population rate of testing for microbiologically confi rmed disease, as indicated by the highest incidence reported from provinces with the highest rates of testing. This fi nding could suggest further underestimation of the incidence of microbiologically confi rmed disease in some provinces caused by lower rates of testing. The peak in incidence of microbiologically confi rmed tuberculosis also varied between provinces. The early decline in incidence recorded in Western Cape was probably related to it being the fi rst province to have introduced an ART programme, coupled with a lower HIV prevalence than other provinces. Conversely, the slower decline noted in Eastern Cape, Northern Cape, and KwaZulu-Natal might have been caused by socioeconomic factors, as well as poorer access to health care in remote rural areas, which is characteristic of these provinces. 25 Limitations of our study are the record-linking algorithm used to identify unique cases in the laboratory database, which could have under-linked or over-linked records. This would have led to a corresponding overestimation or underestimation in incidence. The incompleteness of data from KwaZulu-Natal for 2004 to 2010 required imputation of incidence of microbiologically confi rmed pulmonary tuberculosis by use of data from geographically proximal provinces; nevertheless, the modelled trend in microbiologically confi rmed disease was similar to the recorded trend in new cases registered for treatment. However, the imputed incidence of microbiologically disease in KwaZulu-Natal for this period is likely to be an underestimation for those years, as indicated by this province having the highest incidence during the period 2011-12.
We were unable to disaggregate incidence of microbiologically confi rmed pulmonary tuberculosis by HIV status at a patient level because the HIV data used were only available at a population level; however, since most tuberculosis cases among South African adults (70%) are associated with underlying HIV infection, it is possible that the decline we recorded is mainly related to a decrease in pulmonary tuberculosis among people with HIV infection. IPT coverage in individuals with HIV infection could have also reduced the incidence of microbiologically confi rmed tuberculosis; however, there is little published data on IPT coverage in South Africa. The eff ect of IPT has, however, been noted to be temporary in protecting against tuberculosis in settings such as ours, especially if only provided for 6 months, as was the recommendation during the period under analysis. Consequently, and in view of the poor application of the IPT policy, we consider it unlikely that IPT contributed much to the decline in annual incidence of pulmonary tuberculosis. 26 This postulation is further supported by the decline in pul monary tuberculosis seen in the Western Cape that occurred in tandem with an increase in ART coverage at a time when IPT was unavailable in public health facilities (until 2011). 27 Our direct measurement of a decline in incidence of microbiologically confi rmed pulmonary tuberculosis of 9% since the peak in 2008 is predicted to continue based on recent modelling work suggesting that, with expanded ART eligibility criteria, cumulative incidence of tuberculosis could decline by a further 6-30% by 2033. 28 By takking advantage of the uniqueness of a single laboratory-service provider (NHLS) for over 80% of the population who use public health services, we showed an opportunity to provide robust data on cases of microbiologically confi rmed pulmonary tuberculosis in South Africa, to assess the eff ect of programmatic interventions, and to provide a solution to monitoring progress towards the post-2015 tuberculosis targets.
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